MA47594A - Utilisation de biomarqueurs dans l'identification de patients atteints d'un cancer sensibles à un traitement avec un inhibiteur de prmt5 - Google Patents

Utilisation de biomarqueurs dans l'identification de patients atteints d'un cancer sensibles à un traitement avec un inhibiteur de prmt5

Info

Publication number
MA47594A
MA47594A MA047594A MA47594A MA47594A MA 47594 A MA47594 A MA 47594A MA 047594 A MA047594 A MA 047594A MA 47594 A MA47594 A MA 47594A MA 47594 A MA47594 A MA 47594A
Authority
MA
Morocco
Prior art keywords
biomarkers
treatment
identifying patients
prmt5 inhibitor
cancer sensitive
Prior art date
Application number
MA047594A
Other languages
English (en)
Inventor
Lijs Beke
Dirk Brehmer
Dana Suzanne Gaffney
Christopher H Moy
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MA47594A publication Critical patent/MA47594A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation
MA047594A 2017-02-27 2018-02-26 Utilisation de biomarqueurs dans l'identification de patients atteints d'un cancer sensibles à un traitement avec un inhibiteur de prmt5 MA47594A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762464006P 2017-02-27 2017-02-27

Publications (1)

Publication Number Publication Date
MA47594A true MA47594A (fr) 2020-01-01

Family

ID=61563368

Family Applications (1)

Application Number Title Priority Date Filing Date
MA047594A MA47594A (fr) 2017-02-27 2018-02-26 Utilisation de biomarqueurs dans l'identification de patients atteints d'un cancer sensibles à un traitement avec un inhibiteur de prmt5

Country Status (22)

Country Link
US (2) US11279970B2 (fr)
EP (1) EP3585904B1 (fr)
JP (1) JP7225106B2 (fr)
KR (1) KR102573149B1 (fr)
CN (1) CN110382707A (fr)
AU (1) AU2018225312B2 (fr)
BR (1) BR112019017466A2 (fr)
CA (1) CA3049739A1 (fr)
CL (1) CL2019002438A1 (fr)
CO (1) CO2019008390A2 (fr)
EA (1) EA201992026A1 (fr)
IL (1) IL268842A (fr)
JO (1) JOP20190199B1 (fr)
MA (1) MA47594A (fr)
MX (1) MX2019010150A (fr)
MY (1) MY195860A (fr)
PE (1) PE20191359A1 (fr)
PH (1) PH12019501942A1 (fr)
SG (1) SG11201907607VA (fr)
TN (1) TN2019000212A1 (fr)
UA (1) UA127679C2 (fr)
WO (1) WO2018154104A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202321249A (zh) 2015-08-26 2023-06-01 比利時商健生藥品公司 使用作為ｐｒｍｔ５抑制劑之新穎經６－６雙環芳香環取代之核苷類似物
EA201892031A1 (ru) 2016-03-10 2019-02-28 Янссен Фармацевтика Нв Замещенные аналоги нуклеозидов для применения в качестве ингибиторов prmt5
MX2019003843A (es) 2016-10-03 2019-06-24 Janssen Pharmaceutica Nv Análogos novedosos de carbanucleósidos sustituidos de sistema anular monocíclico y bicíclico para su uso como inhibidores de prmt5.
JP7225106B2 (ja) 2017-02-27 2023-02-20 ヤンセン ファーマシューティカ エヌ．ベー． Ｐｒｍｔ５阻害剤による治療に応答する癌患者の同定におけるバイオマーカーの使用
CN111741964A (zh) * 2017-12-05 2020-10-02 安杰斯制药公司 作为prmt5抑制剂的杂环化合物
CA3084449A1 (fr) 2017-12-08 2019-06-13 Janssen Pharmaceutica Nv Nouveaux analogues spirobicycliques
IL262658A (en) * 2018-10-28 2020-04-30 Memorial Sloan Kettering Cancer Center Prevention of age related clonal hematopoiesis and diseases associated therewith
CA3134613A1 (fr) 2019-04-02 2020-10-08 Aligos Therapeutics, Inc. Composes ciblant prmt5
GB201905780D0 (en) 2019-04-25 2019-06-05 La Thangue Nicholas Cancer therapy
TW202112375A (zh) 2019-06-06 2021-04-01 比利時商健生藥品公司 使用ｐｒｍｔ５抑制劑治療癌症之方法

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4224438A (en) 1970-07-14 1980-09-23 Boehringer Mannheim Gmbh Adenosine-5'-carboxylic acid amides
US6143749A (en) 1995-06-07 2000-11-07 Abbott Laboratories Heterocyclic substituted cyclopentane compounds
CN1331326A (zh) * 2000-06-30 2002-01-16 上海博德基因开发有限公司 一种新的多肽——人精氨酸甲基转移酶(hrmt)32.12和编码这种多肽的多核苷酸
WO2003039523A2 (fr) 2001-11-05 2003-05-15 Exiqon A/S Oligonucleotides modifies a l'aide de nouveaux analogues d'arn-l-alpha
US7034147B2 (en) 2001-11-29 2006-04-25 Irm Llc Nucleoside analog libraries
IL163613A0 (en) 2002-02-19 2005-12-18 Cv Therapeutics Inc Partial and full agonists of a1 adenosine receptors
US20040043959A1 (en) 2002-03-04 2004-03-04 Bloom Laura A. Combination therapies for treating methylthioadenosine phosphorylase deficient cells
AU2002951247A0 (en) 2002-09-06 2002-09-19 Alchemia Limited Compounds that interact with kinases
WO2005005450A1 (fr) 2003-07-15 2005-01-20 Mitsui Chemicals, Inc. Procede de synthese d'un bisdinucleoside cyclique
JP2007537999A (ja) 2003-12-19 2007-12-27 コローニス ファーマシューティカルズ インコーポレイテッド 変異原性複素環
EP1844062A2 (fr) 2005-01-21 2007-10-17 Methylgene, Inc. Inhibiteurs d'adn-methyltransferase
JP2009542608A (ja) 2006-06-29 2009-12-03 アステックス・セラピューティクス・リミテッド 医薬組合せ剤
US20080132525A1 (en) 2006-12-04 2008-06-05 Methylgene Inc. Inhibitors of DNA Methyltransferase
WO2010039548A2 (fr) 2008-09-23 2010-04-08 Alnylam Pharmaceuticals, Inc. Modifications chimiques de monomères et d’oligonucléotides par cycloaddition
US8323918B2 (en) * 2008-12-12 2012-12-04 University Of South Carolina Chloroacetamidine based inhibitors and activity based probes for the protein arginine methytransferases
EP2513298A4 (fr) 2009-12-18 2013-03-27 Harvard College Composés promouvant la réplication des cellules bêta et méthodes d'utilisation de ces composés
WO2012075500A2 (fr) 2010-12-03 2012-06-07 Epizyme, Inc. Modulateurs à base de 7-déazapurine de l'histone méthyltransférase et procédés d'utilisation de ceux-ci
EP2646455A4 (fr) 2010-12-03 2014-04-02 Epizyme Inc Modulateurs d'histone méthyltransférase et leurs procédés d'utilisation
CA2819894A1 (fr) 2010-12-16 2012-06-21 Abbvie Inc. Composes antiviraux
EP2694524B1 (fr) 2011-04-04 2016-05-18 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Dérivés de 2'-o-aminooxyméthyl nucléoside pour l'utilisation dans la synthèse et la modification de nucléosides, nucléotides et oligonucléotides
US20150057243A1 (en) 2012-04-02 2015-02-26 Northern University Compositions and Methods for the Inhibition of Methyltransferases
WO2014035140A2 (fr) 2012-08-30 2014-03-06 Kainos Medicine, Inc. Composés et compositions pour la modulation de l'activité histone méthyltransférase
US20140100184A1 (en) 2012-08-31 2014-04-10 Baylor College Of Medicine Selective inhibitors of histone methyltransferase dot1l
US8940726B2 (en) 2012-12-21 2015-01-27 Epizyme, Inc. PRMT5 inhibitors and uses thereof
EP2935240A1 (fr) 2012-12-21 2015-10-28 Epizyme, Inc. Inhibiteurs de prmt5 et leurs utilisations
UA118548C2 (uk) 2012-12-21 2019-02-11 Епізайм, Інк. Тетрагідро- та дигідроізохіноліни як інгібітори prmt5 та їх застосування
US9611257B2 (en) 2012-12-21 2017-04-04 Epizyme, Inc. PRMT5 inhibitors and uses thereof
US10087151B2 (en) 2014-01-09 2018-10-02 The J. David Gladstone Institutes, A Testimentary Trust Established Under The Will Of J. David Gladstone Substituted benzoxazine and related compounds
EP3160477A4 (fr) 2014-06-25 2018-07-04 Epizyme, Inc. Inhibiteurs de prmt5 et leurs utilisations
CN106999479B (zh) 2014-07-01 2021-07-16 米伦纽姆医药公司 可用作sumo活化酶抑制剂的杂芳基化合物
JP6584521B2 (ja) 2015-02-24 2019-10-02 ファイザー・インク 抗がん剤として有用な置換ヌクレオシド誘導体
TW202321249A (zh) 2015-08-26 2023-06-01 比利時商健生藥品公司 使用作為ｐｒｍｔ５抑制劑之新穎經６－６雙環芳香環取代之核苷類似物
CN108884108B (zh) 2016-03-10 2021-08-31 詹森药业有限公司 用于用作prmt5抑制剂的取代核苷类似物
EA201990851A1 (ru) 2017-02-24 2019-09-30 Янссен Фармацевтика Нв Новые аналоги карбануклеозида, замещенные моноциклической и бициклической кольцевой системой, для применения в качестве ингибиторов prmt5
JP7225106B2 (ja) 2017-02-27 2023-02-20 ヤンセン ファーマシューティカ エヌ．ベー． Ｐｒｍｔ５阻害剤による治療に応答する癌患者の同定におけるバイオマーカーの使用

Also Published As

Publication number Publication date
JOP20190199B1 (ar) 2023-09-17
US20220205026A1 (en) 2022-06-30
WO2018154104A1 (fr) 2018-08-30
EP3585904C0 (fr) 2023-11-29
MY195860A (en) 2023-02-24
MX2019010150A (es) 2019-10-21
BR112019017466A2 (pt) 2020-03-31
EP3585904A1 (fr) 2020-01-01
US20200010881A1 (en) 2020-01-09
CN110382707A (zh) 2019-10-25
JOP20190199A1 (ar) 2019-08-27
EA201992026A1 (ru) 2020-01-24
IL268842A (en) 2019-10-31
AU2018225312A1 (en) 2019-07-25
KR102573149B1 (ko) 2023-08-30
PE20191359A1 (es) 2019-10-01
AU2018225312B2 (en) 2024-02-08
PH12019501942A1 (en) 2020-06-29
CL2019002438A1 (es) 2019-11-29
JP7225106B2 (ja) 2023-02-20
US11279970B2 (en) 2022-03-22
KR20190122677A (ko) 2019-10-30
CA3049739A1 (fr) 2018-08-30
JP2020508048A (ja) 2020-03-19
UA127679C2 (uk) 2023-11-29
TN2019000212A1 (en) 2021-01-07
SG11201907607VA (en) 2019-09-27
EP3585904B1 (fr) 2023-11-29
CO2019008390A2 (es) 2019-08-20

Similar Documents

Publication Publication Date Title
MA47594A (fr) Utilisation de biomarqueurs dans l'identification de patients atteints d'un cancer sensibles à un traitement avec un inhibiteur de prmt5
MA40761A (fr) Utilisation de panels de gènes mutants du fgfr dans l'identification de patients atteints de cancer qui seront sensibles à un traitement avec un inhibiteur du fgfr
MA42043A (fr) Anticorps anti-ox40 et procédés d'utilisation de ceux-ci
MA46566A (fr) Oxystérols et leurs procédés d'utilisation
MA41117A (fr) Imagerie d'un corps
MA46783A (fr) Polythérapie de type thérapie cellulaire t et inhibiteur de btk
UA42295S (uk) Комп'ютер
DK3283880T3 (da) Prognostiske og diagnostiske glycan-baserede biomarkører af hjerneskade
MA54851A (fr) Oxystérols et leurs procédés d'utilisation
MA42409A (fr) Oxystérols et leurs procédés d'utilisation
FR3044684B1 (fr) Inhibiteurs de la corrosion vanadique a base d'yttrium et de magnesium
FR3032786B1 (fr) Systeme de traitement de donnees et de modelisation pour l'analyse de la consommation energetique d'un site
IL281014A (en) Detection and documentation of speeding violations
MA52603A (fr) Solution de récupération de sel et ses procédés d'utilisation
MA45865A (fr) Procédés de détection et de traitement d'une tumeur exprimant pt346 pdk1
MA45573A (fr) Anticorps anti-cd154 et procédés d'utilisation correspondant
FR3031641B1 (fr) Procede d'identification d'une entite
DK3510341T3 (da) Beskyttelsesbeklædningsenhed og anvendelse af denne
FR3043811B1 (fr) Procede d'identification d'une entite
MA50201A (fr) Comprimés de défériprone à libération retardée et procédés d'utilisation correspondants
MA50906A (fr) Inhibiteurs d'immunoprotéasome
MA50887A (fr) Tuyauterie résistante à la corrosion et procédés de fabrication et d'utilisation correspondants
IT201700041695A1 (it) Apparato di misura bio-impedenziometrica di un paziente
FR3014353B1 (fr) Dispositif de traitement d'un corps longiligne
KR102377849B1 (ko) 정보 처리 장치